Machine learning for target discovery in drug development
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
The discovery of macromolecular targets for bioactive agents is currently a bottleneck for the informed design of chemical probes and drug leads. Typically, activity profiling against genetically manipulated cell lines or chemical proteomics is pursued to shed light on their biology and deconvolute drug-target networks. By taking advantage of the ever-growing wealth of publicly available bioactivity data, learning algorithms now provide an attractive means to generate statistically motivated research hypotheses and thereby prioritize biochemical screens. Here, we highlight recent successes in machine intelligence for target identification and discuss challenges and opportunities for drug discovery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Machine learning for molecular and materials science
Butler, K. T., Davies, D. W., Cartwright, H., Isayev, O., & Walsh, A. (2018) · Nature · doi:10.1038/s41586-018-0337-2 · Cited by 4,968 · cited 1×
“[16,17]) as a research hypothesis generator and as a vital method in the chemical biology toolbox for research into drug e target recognition.”
MethodChEMBL: a large-scale bioactivity database for drug discovery
Gaulton, A., Bellis, L. J., Bento, A. P., Chambers, J., Davies, M., Hersey, A., Light, Y., McGlinchey, S., Michalovich, D., Al-Lazikani, B., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr777 · Cited by 4,382
Applications of machine learning in drug discovery and development
Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., Li, B., Madabhushi, A., Shah, P., Spitzer, M., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0024-5 · Cited by 3,228
Automatic Chemical Design Using a Data-Driven Continuous Representation of Molecules
Gómez-Bombarelli, R., Wei, J. N., Duvenaud, D., Hernández-Lobato, J. M., Sánchez-Lengeling, B., Sheberla, D., Aguilera-Iparraguirre, J., Hirzel, T. D., Adams, R. P., & Aspuru-Guzik, A. (2018) · ACS Central Science · doi:10.1021/acscentsci.7b00572 · Cited by 3,106
Clinically applicable deep learning for diagnosis and referral in retinal disease
De Fauw, J., Ledsam, J. R., Romera-Paredes, B., Nikolov, S., Tomasev, N., Blackwell, S., Askham, H., Glorot, X., O’Donoghue, B., Visentin, D., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0107-6 · Cited by 2,639
Ardila, D., Kiraly, A. P., Bharadwaj, S., Choi, B., Reicher, J. J., Peng, L., Tse, D., Etemadi, M., Ye, W., Corrado, G., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0447-x · Cited by 2,167
Planning chemical syntheses with deep neural networks and symbolic AI
Segler, M. H. S., Preuss, M., & Waller, M. P. (2018) · Nature · doi:10.1038/nature25978 · Cited by 1,847 · cited 1×
“For example, deep-learning algorithms have been devised to predict retrosynthetic pathways to molecules of interest [45] and design new chemical entities that can be scrutinized as hits/drug leads [46 e 48].”
BackgroundPredicting new molecular targets for known drugs
Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C., Abbas, A. I., Hufeisen, S. J., Jensen, N. H., Kuijer, M. B., Matos, R. C., Tran, T. B., et al. (2009) · Nature · doi:10.1038/nature08506 · Cited by 1,667
Deep learning enables rapid identification of potent DDR1 kinase inhibitors
Zhavoronkov, A., Ivanenkov, Y. A., Aliper, A., Veselov, M. S., Aladinskiy, V. A., Aladinskaya, A. V., Terentiev, V. A., Polykovskiy, D. A., Kuznetsov, M. D., Asadulaev, A., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0224-x · Cited by 1,573 · cited 1×
“For example, deep-learning algorithms have been devised to predict retrosynthetic pathways to molecules of interest [45] and design new chemical entities that can be scrutinized as hits/drug leads [46 e 48].”
BackgroundImpact of high-throughput screening in biomedical research
Macarron, R., Banks, M. N., Bojanic, D., Burns, D. J., Cirovic, D. A., Garyantes, T., Green, D. V. S., Hertzberg, R. P., Janzen, W. P., Paslay, J. W., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3368 · Cited by 1,364 · cited 1×
“With the advent of high-throughput experimentation, a wealth of chemical and biological data has been generated [16,28,29].”
BackgroundGómez-Bombarelli, R., Aguilera-Iparraguirre, J., Hirzel, T. D., Duvenaud, D., Maclaurin, D., Blood-Forsythe, M. A., Chae, H. S., Einzinger, M., Ha, D.-G., Wu, T., et al. (2016) · Nature Materials · doi:10.1038/nmat4717 · Cited by 1,060 · cited 1×
“Indeed, machine learning has recently seen a range of applications in biology, medicine [32 e 38], chemistry [39 e 41], and materials science [42 e 44], which suggests that it can be used to speed up development pipelines and augment human perception.”
BackgroundReducing safety-related drug attrition: the use of in vitro pharmacological profiling
Bowes, J., Brown, A. J., Hamon, J., Jarolimek, W., Sridhar, A., Waldron, G., & Whitebread, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3845 · Cited by 748 · cited 1×
“Although in some circumstances, such as cancer, it is desirable to harness the potential of therapeutics that modulate a plethora of targets d ideally belonging to distinct signaling pathways [10] d generally, polypharmacology is unwanted because it is responsible for adverse drug reactions [11,12].”
BackgroundTargeting the cancer kinome through polypharmacology
Knight, Z. A., Lin, H., & Shokat, K. M. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2787 · Cited by 674 · cited 1×
“Although in some circumstances, such as cancer, it is desirable to harness the potential of therapeutics that modulate a plethora of targets d ideally belonging to distinct signaling pathways [10] d generally, polypharmacology is unwanted because it is responsible for adverse drug reactions [11,12].”
BackgroundLigand and Target Discovery by Fragment-Based Screening in Human Cells
Parker, C. G., Galmozzi, A., Wang, Y., Correia, B. E., Sasaki, K., Joslyn, C. M., Kim, A. S., Cavallaro, C. L., Lawrence, R. M., Johnson, S. R., et al. (2017) · Cell · doi:10.1016/j.cell.2016.12.029 · Cited by 439
Next-Generation Experimentation with Self-Driving Laboratories
Häse, F., Roch, L. M., & Aspuru-Guzik, A. (2019) · Trends in Chemistry · doi:10.1016/j.trechm.2019.02.007 · Cited by 426
Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474
van Esbroeck, A. C. M., Janssen, A. P. A., Cognetta, A. B., Ogasawara, D., Shpak, G., van der Kroeg, M., Kantae, V., Baggelaar, M. P., de Vrij, F. M. S., Deng, H., et al. (2017) · Science · doi:10.1126/science.aaf7497 · Cited by 332 · cited 1×
“Other prominent examples include the identification of carbamates as arylacetamide deacetylase-like 1 regulators [24] and a clinical-stage imidazole as a promiscuous lipid hydro-lases’ inhibitor [25].”
BackgroundChemical Proteomics Identifies Druggable Vulnerabilities in a Genetically Defined Cancer
Bar-Peled, L., Kemper, E. K., Suciu, R. M., Vinogradova, E. V., Backus, K. M., Horning, B. D., Paul, T. A., Ichu, T.-A., Svensson, R. U., Olucha, J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.051 · Cited by 262
How Chemoproteomics Can Enable Drug Discovery and Development
Moellering, R. E., & Cravatt, B. F. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.01.001 · Cited by 182 · cited 1×
“Downstream identification of the bound proteins can then be made by mass spectrometry or bespoke analytical methods [20].”
BackgroundChemoproteomics and Chemical Probes for Target Discovery
Drewes, G., & Knapp, S. (2018) · Trends in Biotechnology · doi:10.1016/j.tibtech.2018.06.008 · Cited by 132
Chemoproteomic profiling and discovery of protein electrophiles in human cells
Matthews, M. L., He, L., Horning, B. D., Olson, E. J., Correia, B. E., Yates, J. R., Dawson, P. E., & Cravatt, B. F. (2017) · Nature Chemistry · doi:10.1038/nchem.2645 · Cited by 90
Reliable Prediction Errors for Deep Neural Networks Using Test-Time Dropout
Cortés-Ciriano, I., & Bender, A. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00297 · Cited by 51 · cited 1×
“The application of other conceptually distinct regression algorithms is viable [50,51], and one can also expect the growing utility of deep-learning architectures in the target prediction space in the near future [70 e 72].”
Background
Cited by
Serrano, D. R., Luciano, F. C., Anaya, B. J., Ongoren, B., Kara, A., Molina, G., Ramirez, B. I., Sánchez-Guirales, S. A., Simon, J. A., Tomietto, G., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16101328 · Cited by 488
Machine Learning Methods in Drug Discovery
Patel, L., Shukla, T., Huang, X., Ussery, D. W., & Wang, S. (2020) · Molecules · doi:10.3390/molecules25225277 · Cited by 460
Success stories of AI in drug discovery - where do things stand?
Mak, K.-K., Balijepalli, M. K., & Pichika, M. R. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.1985108 · Cited by 51
Current State and Prospects of Artificial Intelligence in Allergy
van Breugel, M., Fehrmann, R. S. N., Bügel, M., Rezwan, F. I., Holloway, J. W., Nawijn, M. C., Fontanella, S., Custovic, A., & Koppelman, G. H. (2023) · Allergy · doi:10.1111/all.15849 · Cited by 43
Metadata
- Authors
- Rodrigues, T., & Bernardes, G. J. L.
- Venue
- Current Opinion in Chemical Biology
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 56
- Pages
- 16-22
- ISSN
- 1367-5931 (ISSN-L)
- OpenAlex
- W2989850839
- Cited by
- 61
- References
- 21
- FWCI
- 0.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.